2024-04-18 16:01:51 ET
Summary
- VKTX has reported positive data from a phase 1 trial of the oral formulation of VK2735, showing a placebo-adjusted weight loss of 3.3% at the highest dose at 28 days.
- There was an absence of plateauing of weight loss at 4 weeks at the higher doses, meaning longer treatment could yield further weight loss.
- Viking plans to continue dose escalation in the current trial meaning further data might not be far ahead, especially if VKTX doses patients for just 4 weeks.
- NVO isn't just relying on semaglutide. It is developing a weight loss drug called amycretin, that is also necessary to consider as competition for VK2735.
...
Read the full article on Seeking Alpha
For further details see:
Viking Therapeutics: An Oral Weight Loss Drug With More Data Ahead